Current and evolving treatment options for limited stage small cell lung cancer

Current Opinion in Oncology

Volumn 18, Issue 2, 2006, Pages 162-172

  Lee, Carrie B ^a   Morris, David E ^a   Fried, Daniel B ^a   Socinski, Mark A ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Chemotherapy; Limited stage small cell lung cancer; PET scan; Radiotherapy

Indexed keywords

AMIFOSTINE; ANTINEOPLASTIC AGENT; BCG VACCINE; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; ETOPOSIDE; FLUORODEOXYGLUCOSE; GROWTH FACTOR; IFOSFAMIDE; IRINOTECAN; MARIMASTAT; MITUMOMAB; MONOCLONAL ANTIBODY; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; TANOMASTAT; TAXANE DERIVATIVE; TIRAPAZAMINE; UNCLASSIFIED DRUG; VANDETANIB; ZOLEDRONIC ACID;

AGE; AGING; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG TREATMENT FAILURE; ESOPHAGITIS; EVALUATION; FATIGUE; FEBRILE NEUTROPENIA; FOLLOW UP; HUMAN; LUNG SMALL CELL CANCER; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; OUTCOME ASSESSMENT; OUTCOMES RESEARCH; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT PLANNING; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY;

EID: 33646672614     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000208790.45312.25     Document Type: Review

References (77)

1. Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999; 340:265-271.
2. Page NC, Read WL, Tierney RM, et al. The epidemiology of small cell lung carcinoma [abstract]. Proceedings of the American Society of Clinical Oncology 2002; 21:1216.
3. Kristjansen PE, Hansen HH. Management of small cell lung cancer: a summary of the Third International Association for the Study of Lung Cancer Workshop on Small Cell Lung Cancer. J Natl Cancer Inst 1990; 82:263-266.
4. Chute JP, Chen T, Feigal E, et al. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999; 17:1794-1801.
5. Gaspar LE, Gay EG, Crawford J, et al. Limited-stage small-cell lung cancer (stages I-III): observations from the National Cancer Data Base. Clin Lung Cancer 2005; 6:355-360. This recent work describes demographics and treatment pattern changes in patients with LS SCLC. Five-year survival rates across cohorts are also reported.
6. Detterbeck FCRM, Socinski MA, Rosenman JG. Diagnosis and treatment of lung cancer: an evidence-based guide for the practicing physician: Philadelphia: W.B. Saunders Company; 2001.
7. Blum R, MacManus MP, Rischin D, et al. Impact of positron emission tomography on the management of patients with small-cell lung cancer: preliminary experience. Am J Clin Oncol 2004; 27:164-171.
8. Chin R Jr, McCain TW, Miller AA, et al. Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study. Lung Cancer 2002; 37:1-6.
9. Hauber HP, Bohuslavizki KH, Lund CH, et al. Positron emission tomography in the staging of small-cell lung cancer: a preliminary study. Chest 2001; 119:950-954.
10. Brink I, Schumacher T, Mix M, et al. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging 2004; 31:1614-1620. This is the largest series to date in which the role of the PET scan in SCLC is addressed.
11. Blanco CQ, Lopez-Picazo JM, Boan J. Initial staging of small-cell lung cancer (SCLC) patients with 18F FDG-PET and conventional imaging techniques [abstract]. Proceedings of the American Society of Clinical Oncology 2003; 22:2618.
12. Bradley JD, Dehdashti F, Mintun MA, et al. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol 2004; 22:3248-3254. This recent trial evaluated the use of the PET scan in staging and radiation planning in patients with LS-SCLC.
13. Evans WK, Shepherd FA, Feld R, et al. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 1985; 3:1471-1477.
14. Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991; 83:855-861.
15. Livingston RB, Moore TN, Heilbrun L, et al. Small-cell carcinoma of the lung: combined chemotherapy and radiation: a Southwest Oncology Group study. Ann Intern Med 1978; 88:194-199.
16. Mascaux C, Paesmans M, Berghmans T, et al. A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 2000; 30:23-36.
17. Mavroudis D, Papadakis E, Veslemes M, et al. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol 2001; 12:463-470.
18. Pujol JL, Carestia L, Daures JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 2000; 83:8-15.
19. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992; 10:282-291.
20. Sundstrom S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002; 20:4665-4672.
21. Skarlos DV, Samantas E, Kosmidis P, et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 1994; 5:601-607.
22. Spigel DR, Hainsworth JD, Burris HA. Long-term follow-up of limited stage small cell lung cancer patients treated with carboplatin-based therapy and radiotherapy by the Minnie Pearl Cancer Research Network (MPCRN). Proceedings of the American Society of Clinical Oncology 2004; 22:7222.
23. Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992; 327:1618-1624.
24. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992; 10:890-895.
25. Bonner JA, Sloan JA, Shanahan TG, et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol 1999; 17:2681-2691.
26. Schild SE, Bonner JA, Shanahan TG, et al. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004; 59:943-951. This is the long-term follow-up of the patients described in the Bonner trial that confirms the benefit of early, aggressive TRT in LS-SCLC.
27. Schild SE, Stella PJ, Brooks BJ, et al. Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly. Cancer 2005; 103:2349-2354. This analysis suggests that elderly patients with LS-SCLC should be treated with combined modality therapy as long as they are carefully monitored.
28. Yuen AR, Zou G, Turrisi AT, et al. Similar outcome of elderly patients in intergroup trial 0096: cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer 2000; 89:1953-1960.
29. Ardizzoni A, Favaretto A, Boni L, et al. Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multi-center phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis: a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study. J Clin Oncol 2005; 23:569-575.
30. Glisson B, Scott C, Komaki R, et al. Cisplatin, ifosfamide, oral etoposide, and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinoma: results of radiation therapy oncology group trial 93-12. J Clin Oncol 2000; 18:2990-2995.
31. Levitan N, Dowlati A, Shina D, et al. Multi-institutional phase I/II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung carcinoma. J Clin Oncol 2000; 18:1102-1109.
32. Bremnes RM, Sundstrom S, Vilsvik J, Aasebo U. Multicenter phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung cancer. J Clin Oncol 2001; 19:3532-3538.
33. Sandler A, Declerck L, Wagner H, et al. A phase II study of cisplatin plus etoposide plus paclitaxel and concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596): an Eastern Cooperative Oncology Group Trial [abstract]. Proceedings of the American Society of Clinical Oncology 2000; 19:1920.
34. Ettinger DS, Berkey BA, Abrams RA, et al. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study. J Clin Oncol 2005; 23:4991-4998. This is the most recent trial to show no benefit for triplet regimens used in combination with TRT in LS-SCLC.
35. Reck M, von Pawel J, Macha HN, et al. Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer. J Natl Cancer Inst 2003; 95:1118-1127.
36. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346:85-91.
37. Kubota K, Nishiwaki Y, Sugiura T, et al. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903. Clin Cancer Res 2005; 11:5534-5538.
38. Mitsuoka S, Kudoh S, Takeda Y, et al. Phase II study of cisplatin, etoposide and concurrent thoracic radiotherapy (TRT) followed by irinotecan and cisplatin in patients with limited stage small-cell lung cancer (SCLC); updated results of WJTOG9902 [abstract]. Proceedings of the American Society of Clinical Oncology 2004; 22:7044.
39. Han JY, Cho KH, Lee DH, et al. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer. J Clin Oncol 2005; 23:3488-3494.
40. Sunpaweravong P, Magree L, Rabinovitch R, et al. A phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer. Invest New Drugs 2005. [Epub ahead of print]
41. Bogart JA, Herndon JE 2nd, Lyss AP, et al. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. Int J Radiat Oncol Biol Phys 2004; 59:460-468.
42. Tsuchiya R, Suzuki K, Ichinose Y, et al. Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101). J Thorac Cardiovasc Surg 2005; 129:977-983. One of very few studies that addresses adjuvant therapy in LS SCLC.
43. Michael M, Babic B, Khokha R, et al. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J Clin Oncol 1999; 17:1802-1808.
44. Shepherd FA, Giaccone G, Seymour L, et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20:4434-4449.
45. Rigas JR, Denham CA, Rinaldi DA, et al. Randomized placebo-controlled trials of the matrix metalloproteinase inhibitor (MMPI), BAY12-9566 as adjuvant therapy for patients with small cell and non-small cell lung cancer [abstract]. Proceedings of the American Society of Clinical Oncology 2003; 22:2525.
46. Dowell J, Amirkhan RH, Lai WS, et al. Survival in small cell lung cancer (SCLC) is independent of vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) expression [abstract]. Proceedings of the American Society of Clinical Oncology 2003; 22:2541.
47. Raefsky EL, Spigel DR, Greco FA, et al. Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by bevacizumab (B) in the treatment of limited-stage small cell lung cancer (SCLC): a phase II trial of the Minnie Pearl Cancer Research Network [abstract]. Proceedings of the American Society of Clinical Oncology 2005; 23:7050.
48. Grant SC, Kris MG, Houghton AN, Chapman PB. Long term survival of patientswith small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. Clin Cancer Res 1999; 5:1319-1323.
49. Giaccone G, Debruyne C, Felip E, et al. Phase III study of adjuvant vaccination with Bec2/Bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971 B; Silva Study). J Clin Oncol 2005; 23:6854-6864. This recently published phase III study failed to show a survival benefit for LS-SCLC patients vaccinated as above.
50. McClay EF, Bogart J, Herndon JE 2nd, et al. A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235). Am J Clin Oncol 2005; 28:81-90.
51. Le QT, McCoy J, Williamson S, et al. Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study. Clin Cancer Res 2004; 10:5418-5424.
52. Kim YH, Girard L, Giacomini CP, et al. Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. Oncogene 2005. [Epub ahead of print]
53. Matsumoto S, Kimura S, Segawa H, et al. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer 2005; 47:31-39.
54. Fried DB, Morris DE, Poole C, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 2004; 22:4837-4845. This meta-analysis is one of two that demonstrated a survival benefit for early, hyperfractionated TRT in LS-SCLC.
55. Pijls-Johannesma MC, De Ruysscher D, Lambin P, et al. Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst Rev 2005; (1):CD004700.
56. Huncharek M, McGarry R. A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer. Oncologist 2004; 9:665-672. The second meta-analysis that shows survival benefit for early, hyperfractionated TRT in LS-SCLC.
57. Chen GY, Jiang GL, Wang LJ, et al. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial. Int J Radiat Oncol Biol Phys 2005; 61:70-75.
58. Komaki R, Swann RS, Ettinger DS, et al. Phase I study of thoracic radiation dose escalation with concurrent chemotherapy for patients with limited small-cell lung cancer: Report of Radiation Therapy Oncology Group (RTOG) protocol 97-12. Int J Radiat Oncol Biol Phys 2005; 62:342-350.
59. Garces YI, Okuno SH, Schild SE, et al. A phase I/II NCCTG trial of escalating doses of twice daily thoracic radiation therapy (TRT) in limited-stage small cell lung cancer (LSCLC) [abstract]. Proceedings of the American Society of Clinical Oncology 2005; 23:7163.
60. Choi NC, Herndon JE 2nd, Rosenman J, et al. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol 1998; 16:3528-3536.
61. Choi NC, Herndon J, Rosenman J. Long term survival data from CALGB 8837: radiation dose escalation and concurrent chemotherapy (CT) in limited stage small cell lung cancer (LD-SCLC). Possible radiation dose-survival relationship [abstract] Proceedings of the American Society of Clinical Oncology 2002; 21:1190.
62. Blackstock AW, Bogart JA, Matthews C, et al. Split-course versus continuous thoracic radiation therapy for limited-stage small-cell lung cancer: final report of a randomized phase III trial. Clin Lung Cancer 2005; 6:287-292.
63. Arquette M, Wasserman T, Govindan R, et al. Phase II evaluation of amifostine as an esophageal mucosal protectant in the treatment of limited-stage small cell lung cancer with chemotherapy and twice-daily radiation. Semin Radiat Oncol 2002; 12 (Suppl 1):59-61.
64. Das SK, Miften MM, Zhou S, et al. Feasibility of optimizing the dose distribution in lung tumors using fluorine-18-fluorodeoxyglucose positron emission tomography and single photon emission computed tomography guided dose prescriptions. Med Phys 2004; 31:1452-1461.
65. Nehmen SA, Erdi YE, Pan T, et al. Four-dimensional (4D) PET/CT imaging of the thorax. Med Phys 2004; 31:3179-3186.
66. Rietzel E, Chen GT, Choi NC, Willet CG. Four-dimensional image-based treatment planning: target volume segmentation and dose calculation in the presence of respiratory motion. Int J Radiat Oncol Biol Phys 2005; 61:1535-1550.
67. Auperin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999; 341:476-484. This meta-analysis demonstrates an absolute survival benefit for the use of PCI in complete responders.
68. Aroney RS, Aisner J, Wesley MN, et al. Value of prophylactic cranial irradiation given at complete remission in small cell lung carcinoma. Cancer Treat Rep 1983; 67:675-682.
69. Arriagada R, Le Chevalier T, Borie F, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst 1995; 87:183-190.
70. Eagan RT, Frytak S, Lee RE, et al. A case for preplanned thoracic and prophylactic whole brain radiation therapy in limited small-cell lung cancer. Cancer Clin Trials 1981; 4:261-266.
71. Gregor A, Cull A, Stephens RJ, et al. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European Organization for Research and Treatment of Cancer (EORTC) Eur J Cancer 1997; 33:1752-1758.
72. Jackson DV Jr, Richards F 2nd, Cooper MR, et al. Prophylactic cranial irradiation in small cell carcinoma of the lung: a randomized study. JAMA 1977; 237:2730-2733.
73. Laplanche A, Monnet I, Santos-Miranda JA, et al. Controlled clinical trial of prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Lung Cancer 1998; 21:193-201.
74. Maurer LH, Tulloh M, Weiss RB, et al. A randomized combined modality trial in small cell carcinoma of the lung: comparison of combination chemotherapy-radiation therapy versus cyclophosphamide-radiation therapy effects of maintenance chemotherapy and prophylactic whole brain irradiation. Cancer 1980; 45:30-39.
75. Niiranen A, Holsti P, Salmo M. Treatment of small cell lung cancer: two-drug versus four-drug chemotherapy and loco-regional irradiation with or without prophylactic cranial irradiation. Acta Oncol 1989; 28:501-505.
76. Ohonoshi T, Ueoka H, Kawahara S, et al. Comparative study of prophylactic cranial irradiation in patients with small cell lung cancer achieving a complete response: a long-term follow-up result. Lung Cancer 1993; 10:47-54.
77. Seydel HG, Creech R, Pagano M, et al. Prophylactic versus no brain irradiation in regional small cell lung carcinoma. Am J Clin Oncol 1985; 8:218-223.